Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 10, 2006, Pages 3507-3513

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Merriam, C Vreni ^a   Warren, Yumi A ^a   Tyrrell, Kerin L ^a   Fernandez, Helen T ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; DOXYCYCLINE; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACTINOMYCES; ACTINOMYCES ODONTOLYTICUS; ACTINOMYCES VISCOSUS; ALISTIPES PUTREDINIS; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTEROIDES; BACTEROIDES UREOLYTICUS; CAMPYLOBACTER GRACILIS; CLOSTRIDIUM BIFERMENTANS; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM CADAVERIS; CLOSTRIDIUM CLOSTRIDIOFORME; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INNOCUUM; CLOSTRIDIUM RAMOSUM; CLOSTRIDIUM TERTIUM; FUSOBACTERIA; FUSOBACTERIUM MORTIFERUM; FUSOBACTERIUM NAVIFORME; FUSOBACTERIUM RUSSII; FUSOBACTERIUM VARIUM; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; LACTOBACILLUS; NONHUMAN; PORPHYROMONAS; PORPHYROMONAS CANORIS; PORPHYROMONAS GINGIVALIS; PORPHYROMONAS SALIVOSA; PORPHYROMONAS SOMERAE; PREVOTELLA; PREVOTELLA BUCCAE; PREVOTELLA DISIENS; PREVOTELLA HEPARINOLYTICA; PREVOTELLA MELANINOGENICA; PREVOTELLA ORALIS; PREVOTELLA ORIS; PRIORITY JOURNAL; VEILLONELLA;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 33749512215     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00499-06     Document Type: Article

References (15)

1. Betriu, C., E. Culebras, M. Gomez, I. Rodriguez-Avial, and J. J. Picazo. 2005. In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother. 56:349-352.
2. Edlund, C., and C. E. Nord. 2000. In vitro susceptibility of anaerobic bacteria to GAR-935, a new glycylcycline. Clin. Microbiol. Infect. Dis. 6:158-164.
3. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,203 recent clinical bacterial isolates. Diag. Microbiol. Infect. Dis. 36:19-36.
4. Jacobus, N. V., L. A. McDermott, R. Ruthazr, and D. R. Snydman. 2004. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48:1034-1036.
5. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, and K. Tyrrell. 2000. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 44:2747-2751.
6. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. Warren, and K. Tyrrell. 2000. Activity of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 44:2389-2394.
7. Goldstein, E. J. C., D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez. 2006. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 50:148-155.
8. Hoban, D. J., S. K. Bouchillion, B. Johnson, J. Johnson, and M. J. Dowzicky. 2005. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52:215-227.
9. Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing Co., Belmont, Calif.
10. Lipsky, B. A., A. R. Berendt, H. G. Deery, J. M. Embil, W. S. Joseph, A. W. Karchmer, J. L. LeFrock, D. P. Lew, J. T. Mader, C. Norden, and J. S. Tan. 2004. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39:885-910.
11. Milatovic, D., F.-J Schmitz, J. Verhoef, and A. C. Fluit. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47:400-404.
12. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken. 2003. Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
13. NCCLS. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6. NCCLS, Wayne, Pa.
14. Peterson, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
15. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, J. C. Wade, et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.